# Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment

> **NCT06726785** · — · RECRUITING · sponsor: **HBC Immunology Inc** · enrollment: 50 (estimated)

## Conditions studied

- Restless Leg Syndrome (RLS)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06726785
- **Lead sponsor:** HBC Immunology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-02-27
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06726785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06726785, "Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment". Retrieved via MORVS 2026-10-26 from https://api.morvs.ai/clinical/NCT06726785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*